LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.
Nadia Harbeck
No relevant relationships to disclose
Seock-Ah Im
Honoraria - LUX Korean Investigator meeting presentation
Research Funding - Az-KCSG Fellowship research fund
Chiun-Sheng Huang
No relevant relationships to disclose
Young-Hyuck Im
No relevant relationships to disclose
Binghe Xu
No relevant relationships to disclose
Sara A. Hurvitz
Research Funding - Boehringer Ingelheim
Keun-Seok Lee
No relevant relationships to disclose
Jin-Hee Ahn
No relevant relationships to disclose
Ajay O. Mehta
No relevant relationships to disclose
Rajender Singh Arora
No relevant relationships to disclose
Qiang Sun
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose
Linu Abraham Jacob
No relevant relationships to disclose
Jacek Jassem
No relevant relationships to disclose
Elzbieta Staroslawka
No relevant relationships to disclose
Jozef Sufliarsky
No relevant relationships to disclose
Marek Wojtukiewicz
No relevant relationships to disclose
Annick Lahogue
Employment or Leadership Position - Boehringer Ingelheim
Martina Maria Uttenreuther-Fischer
Employment or Leadership Position - Boehringer Ingelheim
Martine J. Piccart-Gebhart
Consultant or Advisory Role - Boehringer Ingelheim; GlaxoSmithKline; Roche
Honoraria - Boehringer Ingelheim; GlaxoSmithKline; Roche